Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients.

ABSTRACT:

Background

Tebentafusp has significantly improved overall survival in HLA-A*02:01+ metastatic uveal melanoma (mUM) patients even in those with a best objective response of progressive disease. Thus, strategies to maintain tebentafusp therapy are critical. Here, we examine the efficacy and safety of adding concurrent local therapy (CLT) to tebentafusp upon radiological progression with tebentafusp alone.

Patients and methods

This multicenter retrospective study included mUM patients treated with tebentafusp and CLT, consisting of extrahepatic soft tissue irradiation and liver-directed therapies (LDTs). Efficacy of target and nontarget sites were assessed per RECIST version 1.1. PFS with tebentafusp alone (PFS1) was compared to that after adding CLTs to tebentafusp upon progre

SUBMITTER: Lim TL 

PROVIDER: S-EPMC12574324 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature